CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02658812
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:50.027555+00:00
Published At: 2023-01-25T00:00:00+00:00
Record Updated At: 2023-01-25
Results Posted At: 2023-01-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Chest Wall Neoplasm", "Recurrent Breast Carcinoma", "Recurrent Inflammatory Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Inflammatory Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-01-25"
protocolSection.identificationModule.nctId: "NCT02658812"
protocolSection.identificationModule.officialTitle: "A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-01-25"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.